This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Sarah Auclair
Scientist at Sanofi


Early stage developability and manufacturing risk assessment is needed to ensure selection of well-behaved molecules. As the biologics pipeline begins to diversify with more complex protein therapeutics it may become essential to tailor our approach for each modality. Our developability workflow will be presented along with several case studies where our platform approach needed customization to fully assess the pre-candidates.  

Agenda Sessions

  • Developability: Analytical Platform Approaches for Complex Proteins